Today: 7 February 2026
Subscribe
Browse Category

NYSE:LLY News 29 January 2026 - 4 February 2026

Eli Lilly stock in focus before earnings after Novo warns on obesity-drug price squeeze

Eli Lilly stock in focus before earnings after Novo warns on obesity-drug price squeeze

Eli Lilly shares fell 0.5% to $998.50 in premarket trading Wednesday after a 4% drop Tuesday, following Novo Nordisk’s warning of up to a 13% drop in 2026 sales and profits. Novo cut prices and launched an oral Wegovy, while Lilly plans to cap higher-dose obesity drug prices at $399 per month for repeat cash buyers. Investors await Lilly’s Q4 results and comments on pricing and competition.
4 February 2026
····
Eli Lilly stock price drops 4% as Novo outlook jars weight-loss trade ahead of earnings

Eli Lilly stock price drops 4% as Novo outlook jars weight-loss trade ahead of earnings

Eli Lilly shares fell 3.9% to $1,003.46 on Tuesday, tracking a sharp 14% drop in Novo Nordisk after its 2026 forecast signaled deeper pricing pressure in the obesity-drug market. Pfizer also slipped on new weight-loss drug data. Lilly will report quarterly results Wednesday, as investors watch for signs of further price cuts and shifting demand in the sector.
4 February 2026
·····
Eli Lilly stock slips as obesity-drug price cuts and rival data set up Feb. 4 earnings

Eli Lilly stock slips as obesity-drug price cuts and rival data set up Feb. 4 earnings

Eli Lilly shares fell 1.4% to $1,029.99 by midday Tuesday as U.S. prices for GLP-1 obesity drugs dropped sharply, prompting analysts to cut long-term forecasts. Novo Nordisk and Pfizer reported strong weight-loss data for rival drugs this week, intensifying competition. Investors await Lilly’s earnings update Wednesday for signals on pricing, demand, and supply outlooks.
3 February 2026
······
Eli Lilly stock price climbs as obesity-drug forecasts get a reality check before earnings

Eli Lilly stock price climbs as obesity-drug forecasts get a reality check before earnings

Eli Lilly shares rose 1.5% to close near $1,052.70 Monday, recovering from early losses ahead of its earnings report due Wednesday. Analysts have cut long-term forecasts for obesity drugs as prices fall and competition intensifies, with 2030 sales estimates for GLP-1 drugs dropping to about $100 billion. Investors are focused on Lilly’s pricing strategy and demand outlook. The FDA is set to rule on Lilly’s weight-loss pill by April 10.
2 February 2026
·····
Eli Lilly stock: LLY ends higher after $3.5 billion Pennsylvania plant plan as earnings near

Eli Lilly stock: LLY ends higher after $3.5 billion Pennsylvania plant plan as earnings near

Eli Lilly shares closed Friday up 1.3% at $1,037.15 after announcing a $3.5 billion injectable weight-loss drug plant in Pennsylvania. The facility, set for Fogelsville, will create 850 permanent jobs and is expected to open in 2031. Pennsylvania will contribute $100 million. Investors await Lilly’s Feb. 4 earnings release.
1 February 2026
·····
Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Eli Lilly shares rose 1.3% after announcing a $3.5 billion Pennsylvania plant for obesity drugs, helping the Health Care Select Sector SPDR Fund gain 0.6% as the S&P 500 fell. Biotech lagged, with Corcept Therapeutics dropping 10.6% after an FDA rejection. Thermo Fisher slid 2.3% on weak profit guidance. Stryker jumped 4.3% after raising its outlook.
31 January 2026
··········
Eli Lilly stock price (LLY): $3.5B plant, EU Mounjaro call and earnings ahead — what to watch

Eli Lilly stock price (LLY): $3.5B plant, EU Mounjaro call and earnings ahead — what to watch

Eli Lilly shares rose 1.3% to $1,037.15 after announcing a $3.5 billion injectable drug plant in Pennsylvania, set to create 850 permanent jobs by 2031. The plant will produce next-generation weight-loss drugs, including retatrutide. The European regulator declined a new use for Mounjaro in heart failure but will update prescribing info. Lilly’s Q4 results are due Feb. 4.
31 January 2026
·····
Eli Lilly stock climbs after $3.5 billion Pennsylvania plant plan as traders eye Feb. 4 results

Eli Lilly stock climbs after $3.5 billion Pennsylvania plant plan as traders eye Feb. 4 results

Eli Lilly shares rose 1.3% to $1,037.15 in after-hours trading Friday after announcing a $3.5 billion facility in Fogelsville, Pennsylvania to produce injectable weight-loss drugs, including retatrutide. Pennsylvania will contribute $100 million to the project, which is expected to create 850 permanent jobs and start operations by 2031.
31 January 2026
·····
Eli Lilly stock climbs after $3.5 billion Pennsylvania plant plan as investors eye earnings

Eli Lilly stock climbs after $3.5 billion Pennsylvania plant plan as investors eye earnings

Eli Lilly shares rose 1.6% to $1,040.80 midday Friday after announcing a $3.5 billion injectable drug plant near Allentown, Pennsylvania, set to open by 2031. Pennsylvania will provide $100 million for the project. Lilly also signed a $1.93 billion autoimmune research deal with Repertoire. Quarterly results are due Feb. 4.
30 January 2026
·····
Eli Lilly stock barely budges after $1.93bn autoimmune pact; Trump touts six U.S. plants

Eli Lilly stock barely budges after $1.93bn autoimmune pact; Trump touts six U.S. plants

Eli Lilly shares closed up 0.03% at $1,024.14 after announcing new research deals in autoimmune disease and gene-editing for hearing loss. Repertoire Immune Medicines will receive $85 million upfront in a collaboration potentially worth $1.84 billion. Lilly also signed a gene-editing agreement with Seamless Therapeutics valued up to $1.12 billion. Investors await Feb. 4 earnings for updates on demand and supply.
30 January 2026
·····
Eli Lilly stock price today: LLY rises on $1.93 billion Repertoire deal as earnings near

Eli Lilly stock price today: LLY rises on $1.93 billion Repertoire deal as earnings near

Eli Lilly shares rose 0.5% Thursday after Repertoire Immune Medicines announced a partnership with the company worth up to $1.93 billion. The deal follows Lilly’s $1.12 billion gene-editing agreement targeting hearing loss. Investors are also watching for Medicare’s plan to include Trulicity in upcoming price negotiations. Lilly’s earnings report is expected Feb. 4.
29 January 2026
······
Eli Lilly stock drops after hours: Medicare pricing talks and GLP-1 battle back in focus

Eli Lilly stock drops after hours: Medicare pricing talks and GLP-1 battle back in focus

Eli Lilly shares fell about 1.5% to $1,023.80 in after-hours trading Wednesday after U.S. Medicare added Trulicity to its drug-price negotiation list, setting a Feb. 28 participation deadline. Lilly also signed a deal worth up to $1.12 billion with Seamless Therapeutics to develop gene-editing treatments for hearing loss.
29 January 2026
····
1 2 3 4 … 13

Stock Market Today

Lloyds share price steadies after buyback update and BoE rate jitters — what to watch next week

Lloyds share price steadies after buyback update and BoE rate jitters — what to watch next week

7 February 2026
Lloyds shares closed up 0.9% at 106.75 pence Friday after the bank announced fresh buybacks totaling 17 million shares over two days, all to be cancelled. The stock rebounded from a 5.6% drop Thursday as traders adjusted UK rate-cut bets. About 121 million Lloyds shares changed hands. Investors await the bank’s annual report on February 18 and the next Bank of England decision March 19.
Vodafone shares steady up after Q3 wobble — Germany, buyback and next results now set the tone

Vodafone shares steady up after Q3 wobble — Germany, buyback and next results now set the tone

7 February 2026
Vodafone shares rose 1.47% to 110.60p Friday, recovering part of Thursday’s 4.68% drop after a Q3 update. Group revenue climbed 6.5% to €10.5 billion, but Germany’s 0.7% service revenue growth missed some forecasts. Vodafone launched a new €500 million buyback tranche, bringing total buybacks since May to €3.5 billion. Investors remain focused on Germany’s pace and cash flow execution.
NatWest Group stock: buyback filing and Rightmove mortgage deal set up a busy week

NatWest Group stock: buyback filing and Rightmove mortgage deal set up a busy week

7 February 2026
NatWest shares closed up 1.45% at 659.4 pence Friday, buoyed by a buyback of 797,428 shares and a new digital mortgage deal with Rightmove. The Bank of England held rates at 3.75% but signaled possible cuts, with markets pricing in two reductions for 2026. NatWest plans to expand its Accelerator community to 50,000 members by 2026. Annual results are due Feb. 13.
Unilever share price holds at 5,250p as results week looms — what investors watch next

Unilever share price holds at 5,250p as results week looms — what investors watch next

7 February 2026
Unilever shares closed flat at 5,250p in London Friday, underperforming the FTSE 100’s 0.6% gain. The company issued 4.2 million new shares for employee plans, bringing total shares to over 2.18 billion. Investors await Q4 and full-year results on Feb. 12, with analyst consensus pointing to 3.9% Q4 sales growth. Unilever’s U.S. ADR rose 0.8% to $72.12.
Go toTop